Physician profile
Scott E Altschuler
NPI 1346453610
$2,494.71
in general payments reported to CMS, 2019-2025
26 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $53.74 · 2021: $155 · 2022: $350 · 2023: $466 · 2024: $543 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.11 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $406.97 | 2022-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $357.58 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.68 | 2019-2024 | Xifaxan, Trulance |
| Intuitive Surgical, INC. | $232.33 | 2019-2022 | |
| Evoke Pharma, INC. | $224.17 | 2022-2025 | Gimoti |
| Abbvie INC. | $167.44 | 2019-2025 | Skyrizi, Rinvoq |
| Nestle Healthcare Nutrition INC. | $147.86 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $98.58 | 2024-2025 | Zenpep, Vowst |
| Braintree Laboratories, INC. | $85.68 | 2021-2024 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $83.15 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $60.32 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $42.46 | 2020-2021 | |
| Medtronic, INC. | $36.44 | 2023 | Pillcam, Interstim |
| Merck Sharp & Dohme LLC | $30.44 | 2021-2022 | |
| Vivus LLC | $29.92 | 2025 | Pancreaze |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $29.07 | 2023-2025 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $24.92 | 2023 | Linzess |
| Novo Nordisk INC | $24.14 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Gilead Sciences, INC. | $21.70 | 2025 | |
| Daiichi Sankyo INC. | $20.48 | 2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $19.54 | 2023 | Entyvio |
| Ipsen Biopharmaceuticals, INC | $18.90 | 2025 | Iqirvo |
| Genzyme Corporation | $17.81 | 2024 | |
| Covidien Lp | $15.62 | 2019 | |
| Rayner Intraocular Lenses Limited | $13.35 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Altschuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.